|
|
|
|
|
Legal status
Patent lapsed (non-payment of fees)
| (51) | INT.CL. | C07D 403/12 | (2006.01) |
| C07D 205/04 | (2006.01) | ||
| A61K 31/506 | (2006.01) | ||
| A61P 37/00 | (2006.01) | ||
| A61P 29/00 | (2006.01) |
| (11) | Number of the document | 3255043 |
| (13) | Kind of document | T |
| (96) | European patent application number | 16202983.9 |
| Date of filing the European patent application | 2012-07-10 | |
| (97) | Date of publication of the European application | 2017-12-13 |
| (45) | Date of publication and mention of the grant of the patent | 2021-01-20 |
| (46) | Date of publication of the claims translation | 2021-04-12 |
| (30) | Number | Date | Country code |
| 201161506737 P | 2011-07-12 | US |
| (72) |
CONNOLLY, Stephen, GB
EBDEN, Mark, Richard, GB
LANGER, Thomas, GB
STEVEN, Alan, Robert, GB
STEWART, Craig, Robert, GB
TOMLIN, Paula, Margaret, GB
WALTERS, Iain, Alastair, Stewart, GB
WILLIAMS, Andrew, John, GB
|
| (73) |
AstraZeneca AB,
151 85 Södertälje,
SE
|
| (74) |
Reda ŽABOLIENĖ,
METIDA, Verslo centras "VERTAS", Gynėjų g. 16, LT-01109 Vilnius,
LT
|
| (54) | N-(6-((2R,3S)-3,4-dihidroksibutan-2-iloksi)-2-(4-fluorbenziltio)pirimidin-4-il)-3- metilazetidin-1-sulfonamidas kaip chemokino receptoriaus moduliatorius |
| N-(6-((2R,3S)-3,4-DIHYDROXYBUTAN-2-YLOXY)-2-(4-FLUOROBENZYLTHIO)PYRIMIDIN-4-YL)-3- METHYLAZETIDINE-1-SULFONAMIDE AS CHEMOKINE RECEPTOR MODULATOR |
| Payment date | Validity (years) | Amount | |
| 2022-06-20 | 11 | 289.00 EUR |
| Patent lapsed (non-payment of fees) | ||
| Invalidation date | 2023-07-10 |